Summary
Global Markets Direct’s, ‘Degenerative Disc Disease - Pipeline Review, H2 2016’, provides an overview of the Degenerative Disc Disease pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Degenerative Disc Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Degenerative Disc Disease and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Degenerative Disc Disease
- The report reviews pipeline therapeutics for Degenerative Disc Disease by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Degenerative Disc Disease therapeutics and enlists all their major and minor projects
- The report assesses Degenerative Disc Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Degenerative Disc Disease
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Degenerative Disc Disease
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Degenerative Disc Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
AnGes MG, Inc.
Asterias Biotherapeutics, Inc.
Biogenomics Limited
Biopharm GmbH
BioRestorative Therapies, Inc.
Bone Therapeutics SA
DiscGenics, Inc.
ISTO Technologies, Inc.
TissueGene, Inc.
Yuhan Corporation
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Degenerative Disc Disease Overview 8
Therapeutics Development 9
Pipeline Products for Degenerative Disc Disease - Overview 9
Pipeline Products for Degenerative Disc Disease - Comparative Analysis 10
Degenerative Disc Disease - Therapeutics under Development by Companies 11
Degenerative Disc Disease - Therapeutics under Investigation by Universities/Institutes 12
Degenerative Disc Disease - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Unknown Stage Products 16
Degenerative Disc Disease - Products under Development by Companies 17
Degenerative Disc Disease - Products under Investigation by Universities/Institutes 18
Degenerative Disc Disease - Companies Involved in Therapeutics Development 19
AnGes MG, Inc. 19
Asterias Biotherapeutics, Inc. 20
Biogenomics Limited 21
Biopharm GmbH 22
BioRestorative Therapies, Inc. 23
Bone Therapeutics SA 24
DiscGenics, Inc. 25
ISTO Technologies, Inc. 26
TissueGene, Inc. 27
Yuhan Corporation 28
Degenerative Disc Disease - Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Target 30
Assessment by Mechanism of Action 32
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
ALLOB - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
AMG-0101 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
AMG-0103 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
BRTX-100 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
CHND-1 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
dibotermin alfa - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
NuQu - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
Peptides to Antagonize IL-1 Receptor for Dermatology, Musculoskeletal and CNS Disorders - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
Poly N-Acetyl Glucosamine Hydrogel - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
Recombinant Protein for Bone Fracture, Degenerative Disc Disease, Erectile Dysfunction and Parkinson's Disease - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
Small Molecules for Degenerative Disc Disease - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
Stem Cell Therapy for Degenerative Disc Disease - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
TG-D - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
X-0002 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
YH-14618 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
Degenerative Disc Disease - Dormant Projects 59
Degenerative Disc Disease - Product Development Milestones 60
Featured News & Press Releases 60
May 03, 2016: Bone Therapeutics completes recruitment of its ALLOB Phase IIA spinal fusion study 60
Feb 24, 2016: Bone Therapeutics Presents ALLOB Pre-Clinical and Early Clinical Efficacy Data in Spinal Fusion at the ‘Clinical Applications of Stem Cells’ Conference 60
Feb 17, 2016: Bone Therapeutics treats 12 patients without safety concerns in ALLOB Phase IIA spinal fusion trial 61
Feb 09, 2016: BioRestorative Therapies Names Lead Cell-Based Lumbar Disc Therapeutic Product 61
Jan 12, 2015: BioRestorative Therapies Reports Successful Meeting with FDA 62
Nov 24, 2014: BioRestorative Therapies Schedules Pre-IND Meeting With FDA 62
Oct 09, 2014: BioRestorative Therapies Engages Access BIO to Support Advancement of brtxDISC Program into Clinical Studies 63
Sep 15, 2014: Bone Therapeutics receives clearance for ALLOB phase II trial in spine fusion 63
Appendix 65
Methodology 65
Coverage 65
Secondary Research 65
Primary Research 65
Expert Panel Validation 65
Contact Us 65
Disclaimer 66
List of Tables
Number of Products under Development for Degenerative Disc Disease, H2 2016 9
Number of Products under Development for Degenerative Disc Disease - Comparative Analysis, H2 2016 10
Number of Products under Development by Companies, H2 2016 11
Number of Products under Investigation by Universities/Institutes, H2 2016 12
Comparative Analysis by Late Stage Development, H2 2016 13
Comparative Analysis by Clinical Stage Development, H2 2016 14
Comparative Analysis by Early Stage Development, H2 2016 15
Comparative Analysis by Unknown Stage Development, H2 2016 16
Products under Development by Companies, H2 2016 17
Products under Investigation by Universities/Institutes, H2 2016 18
Degenerative Disc Disease - Pipeline by AnGes MG, Inc., H2 2016 19
Degenerative Disc Disease - Pipeline by Asterias Biotherapeutics, Inc., H2 2016 20
Degenerative Disc Disease - Pipeline by Biogenomics Limited, H2 2016 21
Degenerative Disc Disease - Pipeline by Biopharm GmbH, H2 2016 22
Degenerative Disc Disease - Pipeline by BioRestorative Therapies, Inc., H2 2016 23
Degenerative Disc Disease - Pipeline by Bone Therapeutics SA, H2 2016 24
Degenerative Disc Disease - Pipeline by DiscGenics, Inc., H2 2016 25
Degenerative Disc Disease - Pipeline by ISTO Technologies, Inc., H2 2016 26
Degenerative Disc Disease - Pipeline by TissueGene, Inc., H2 2016 27
Degenerative Disc Disease - Pipeline by Yuhan Corporation, H2 2016 28
Assessment by Monotherapy Products, H2 2016 29
Number of Products by Stage and Target, H2 2016 31
Number of Products by Stage and Mechanism of Action, H2 2016 33
Number of Products by Stage and Route of Administration, H2 2016 35
Number of Products by Stage and Molecule Type, H2 2016 37
Degenerative Disc Disease - Dormant Projects, H2 2016 59
List of Figures
Number of Products under Development for Degenerative Disc Disease, H2 2016 9
Number of Products under Development for Degenerative Disc Disease - Comparative Analysis, H2 2016 10
Number of Products under Development by Companies, H2 2016 11
Number of Products under Investigation by Universities/Institutes, H2 2016 12
Comparative Analysis by Clinical Stage Development, H2 2016 14
Comparative Analysis by Early Stage Products, H2 2016 15
Assessment by Monotherapy Products, H2 2016 29
Number of Products by Targets, H2 2016 30
Number of Products by Stage and Targets, H2 2016 30
Number of Products by Mechanism of Actions, H2 2016 32
Number of Products by Stage and Mechanism of Actions, H2 2016 32
Number of Products by Routes of Administration, H2 2016 34
Number of Products by Stage and Routes of Administration, H2 2016 34
Number of Products by Molecule Types, H2 2016 36
Number of Products by Stage and Molecule Types, H2 2016 36
